Mild Cognitive Impairment (MCI) may be a precursor of Alzheimer's disease (AD). There is a boundary area between normal aging and dementia. In practice, the term "age related cognitive decline" has been used interchangeably with "normal aging". Alternatively, the term "aging associated cognitive decline" was introduced and defined by a performance on a standardized cognitive scale focused on learning and memory, attention and cognitive speed, language, or visuoconstructional abilities. The term "mild cognitive impairment" was adopted by Petersen in 2004 to describe a period in the course of neurodegenerative disease where cognition is no longer normal relative to age expectations, however, daily functions are not sufficiently disrupted to correlate with the diagnosis of dementia. Most of the literature refers to the amnestic form of MCI, which is likely a precursor of AD. The rate of conversion from amnestic form of MCI to AD is estimated to reach 10-15% per year. That is why MCI generated a great deal of research. When considering MCI a precursor of AD, it seems reasonable to study AD genetic markers in the MCI patients. In AD, association studies focus on genetic polymorphisms assumed to have an effect on the expression and modulation function of genes associated with AD pathogenesis (ApoE, APP, presenilin 1, presenilin 2, tau protein), and on polymorphisms related to metabolism of the aforementioned proteins (splicing, degradation). Neuropsychological assesment plays a substantial role in the diagnosis of MCI, especially in the case of identification of different MCI subtypes or typical profiles of cognitive performance in prodromal phases of neurodegenerative diseases. The optimal composition of diet may increase an average age and prevent impairment of cognitive functions at the same time. Despite the progress in early diagnosis of MCI and dementia, further research is needed on differential diagnosis and treatment. In amnestic subtype of MCI some genetic markers may already be present, predicting possible future development of AD. Pointing to the need of secondary prevention, lifestyle modifications and possible early treatment could be implemented.
What is the Mild Cognitive Impairment?
There is a boundary area between normal aging and dementia. An extensive nomenclature exists to describe this boundary. Principally two forms of a cognitive change are associated with aging. One form involves benign changes in cognition associated with nonspecific histopathological brain changes. The other one is a malignant form which includes cognitive and behavioural changes with a specific brain histopathology.
In practice, the term "age related cognitive decline" has been used interchangeably with "normal aging" (1) . On the other hand, there is the term "mild cognitive impairment" describing the course of a neurodegenerative disease where cognition is not normal relative to age expectations, but daily functions are not disturbed to qualify for the diagnosis of dementia (2) .
Alternatively, the term "aging associated cognitive decline" (AACD) was introduced by Levy in 1994 (3) and defined by a performance on a standardized cognitive test that is at least one standard deviation below age-adjusted norms in at least one of any of the following cognitive domains: learning and memory, attention and cognitive speed, language, or visuoconstructional abilities. In addition to that, there should be no medical, psychiatric or neurological disorder that could cause cognitive impairment including dementia and normal activities of daily living should be preserved. Pantel et al. (4) demonstrated that parahippocampal brain volumes in patients meeting AACD criteria were intermediate between cognitively intact elderly individuals and individuals meeting criteria for Alzheimer's disease. Because of this, it seems suitable that AACD criteria could be a feasible approach for establishing diagnostic criteria for preclinical or potentially prodromal Alzheimer's dementia.
The term "mild cognitive impairment" (MCI) was initially introduced by Reisberg in 1982 but Petersen in 2004 (5) adopted this term to describe a period in the course of neurodegenerative disease where cognition is no longer normal relative to age expectations, but also where daily functions are not sufficiently disrupted to correlate with the diagnosis of dementia. In 2005, Petersen and Morris (6) distinguished amnestic and nonamnestic forms of MCI which might be associated with different underlying aetiologies like Alzheimer's disease or vascular dementia.
Most of the literature refers to the amnestic form of MCI, which is likely a precursor of Alzheimer's disease. The rate of conversion from amnestic form of MCI to Alzheimer's disease is estimated to be 10-15% per year. That is why MCI generated a great deal of research (7) .
There are also some other emerging terms like "major neurocognitive disorder" and "minor neurocognitive disorder" but it is a question if they are going to be broadly adopted. There is a consensus in progress how to identify prodromes for nearly all neurodegenerative dementias and distinguish MCI from a typical cognitive aging.
We can start to use different biomarkers, neuroimaging, genetics and sensitive cognitive measures to identify dementia risk before cognitive impairment develops, but neuropsychological assessment will continue to play an important role in intervention planning, assessment of care needs and tracking the course of illness for the individual patient with dementia.
If we accept that MCI may be a precursor of Alzheimer's disease, it is useful to study genetic markers in MCI patients, which play a role in Alzheimer's disease. In the current genetic research, one of the most frequently used methods for studying multifactorial diseases such as AD are association studies. These are based on comparing allele and genotype frequencies between the studied groups of persons. In AD, association studies focus on genetic polymorphisms assumed to have an effect on the expression and modulation function of genes associated with AD pathogenesis (ApoE, APP, presenilin 1, presenilin 2, tau protein) and on polymorphisms related to metabolism of the aforementioned proteins (splicing, degradation). Selection of the so-called candidate genes results from the knowledge of pathological processes in AD. In candidate genes, the so-called functional polymorphisms are most frequently selected, in which the effect on gene function has been proved (most often influencing the level of expression). As far the genetic risk factors are concerned, early-onset familial AD is assumed to be frequently caused by autosomal dominant mutations in the genes for APP (amyloid precursor protein), presenilin 1 and presenilin 2. This form of AD accounts for 2-5% of all AD cases. First-degree relatives of AD patients have a higher lifetime risk of developing the disease than the other populations. This increased risk and familial aggregation of AD cases are contributed to both genetic and other factors. From genetic factors, the risk may be partly due to the presence of the apolipoprotein E (APOE) e4 allele, but the other genes may also play a role in the development of the disease. The e4 allele is so far the only confirmed genetic factor for the development of both early-and late-onset AD. It is a factor increasing susceptibility to AD; however, it is neither necessary nor sufficient for its development. Homozygotes for the e4 allele have a higher risk of AD and the age of its manifestation decreases. DNA polymorphisms of dozens of other candidate genes have been studied to reveal their relation to AD pathogenesis. Of those, some were shown as a risk. These are, for example, polymorphisms in the genes for nicastrin, ECE1, ACE, IDE, neprilysin, CHAT, ABCA1, CYP46, APOA1, IL-1, HLA A2, TNF A, cystatin C, PRNP, BACE1 and BACE2 (8) .
In amnestic subtype of MCI some genetic markers may already be present, predicting possible future development of AD. In these persons, secondary prevention could be implemented in the form of both lifestyle modifications and possible early treatment.
Nikolaj et al. in their study stressed the fact that neuropsychological assesment plays a substantial role in the diagnosis of MCI, especially in the case of identification of different MCI subtypes or cognitive performance in prodromal phases of neurodegenerative diseases. Therefore, it is necessary to take into account the whole battery of presented methods such as neuropsychological assessment, magnetic resonance, biochemical, genetic and neuropsychiatric examination etc. (9) .
One of the possibilities to increase average age in the population and prevent impairment of cognitive functions at the same time is optimal composition of a diet. Food usually does not supply organism with essential nutrients in adequate quantities. Out of different food components, it is supposed that PUFA, vitamins B9 and B12 or ginkgo biloba may contribute to optimal course of aging. Also individuals with mental disorders are consuming various dietary supplements with possible positive but also negative effects. It is therefore necessary to consult this topic with each patient individually (10) .
Important biomarker of AD is early disturbance of episodic memory which may be present in MCI (11) .
Another risk factor for dementia is smoking (12) which together with vascular changes caused by atherosclerosis may account for almost 40% of all dementia cases. Pathological processes subsequent to vascular changes caused by smoking bound together with the lack of oxygen or decreased blood flow then might cause the same effects increasing the probability of dementia onset even in a young person (13) .
Even if a progress has been made in the early diagnosis of MCI and dementia, further research is needed to advance the utility of neuropsychological measures and genetic markers in differential diagnosis, prediction of progression and treatment planning (14, 15) .
